Trials / Recruiting
RecruitingNCT03174977
Pharmacokinetics Distribution of Raltegravir by PET/MR
Pharmacokinetics Distribution of Raltegravir Using Radiolabeling in HIV-infected Patients by PET/MR: a Pilot Study.
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center drug distribution and pharmacokinetic study of a single microdose of 18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a raltegravir-containing ART regimen. After administration of IV 18F-raltegravir, subjects will undergo PET/MRI in order to determine the distribution of radiolabeled drug through the lymphoreticular system and other tissues throughout the entire body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-Raltegravir | A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy. |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2024-11-01
- Completion
- 2025-01-01
- First posted
- 2017-06-05
- Last updated
- 2024-06-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03174977. Inclusion in this directory is not an endorsement.